Investors
Information Disclosure
-
VOLUNTARY ANNOUNCEMENT - PRESENTATION OF THE PHASE II CLINICAL STUDY DATA ON KRAS G12C INHIBITOR “GARSORASIB TABLET (D-1553)”2024.04.11
-
VOLUNTARY ANNOUNCEMENT - DATA OF 6 STUDIES REGARDING “ANLOTINIB HYDROCHLORIDE CAPSULES”, “TQB2916 (CD40 AGONIST)” AND “FHND6091 (PROTEASOME INHIBITOR)” WERE PRESENTED AT 2024 AACR2024.04.10
-
VOLUNTARY ANNOUNCEMENT - ENTER INTO STRATEGIC PARTNERSHIP WITH BOEHRINGER INGELHEIM ON INNOVATIVE ONCOLOGY PORTFOLIO IN CHINA2024.04.08
-
VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO RESTRICTED SHARE AWARD SCHEME2024.04.08
-
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 MARCH 20242024.04.02
-
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 20232024.03.28
-
FINAL DIVIDEND FOR 20232024.03.28
-
VOLUNTARY ANNOUNCEMENT - APPROVAL FOR MARKETING OF “IOPROMIDE INJECTION”2024.03.25